Key Takeaways:
-
MVA-N RSV showed some efficacy but missed significance in the co-primary endpoint.
Bavarian Nordic A/S’s respiratory syncytial virus (RSV) vaccine candidate, MVA-BN RSV, has missed the mark in the Phase III VANIR trial in older adults, but the firm is confident it can meet its financial guidance with the help of a strong mpox franchise and promising late-stage candidates.
VANIR randomized more than 20,000 people aged 60 or older to a single dose of MVA-BN RSV or placebo, measuring...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?